Abstract PS4-03-12: Quantifyher (trial in progress): quantitative immunofluorescence and/or messenger rna to measure her2 expression in patients with metastatic breast cancer treated with trastuzumab deruxtecan (tbcrc066)
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Authors: E. P. Taranto, W. Fawn, C. Desirae, E. Walinsky, S. Deluca, L. Bayne, E. P. Wileyto, A. Shirali, C. J. Robbins, Y. Abdou, J. Anampa, M. Balic, J. V. Canzoniero, N. C. Chen, F. Howard, L. Huppert, A. Kahn, C. Mainor, J. Mouabbi, V. Nair, T. Degeer, J. Weidler, T. McNicholas, C. Serway, J. Reischl, M. Bates, R. Monroe, D. L. Rimm, A. DeMichele
Institutions: University of Pennsylvania, Yale University, University of North Carolina at Chapel Hill, Montefiore Einstein Comprehensive Cancer Center, University of Pittsburgh, UPMC Hillman Cancer Center, Johns Hopkins University, Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center, Baylor College of Medicine, University of Chicago, University of California, San Francisco, Georgetown University, The University of Texas MD Anderson Cancer Center, University of Washington, Fred Hutch Cancer Center, Danaher (United Kingdom), Cepheid (United States), Danaher (United States)
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129190590
Cites:
Cited by:
Related to: